No abstract

of diagnosis became dialysis independent. Median creatinine clearences of patients with CrCl <60 ml/min before and after ASCT was 25.45 ml/ min and 54.39 ml/min respectively. CrCl increased above 60 ml/min in 11 patients. CrCl increased %50 above baseline in 18 patients. Summary/Conclusion: In conclusion treatment response rates and progression-free survival rates were not affected by renal failure. Treatment of patients with renal insufficiency should not be different than those of patients who do not have renal failure. Standard myeloma treatment and ASCT should be used in these patients; melphalan dose can be reduced to 140 mg/m2 in patients with CrCl <60 ml/min.